Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

Publisher： Karger

E-ISSN： 1423-0232|86|4|191-198

ISSN： 0030-2414

Source： Oncology, Vol.86, Iss.4, 2014-04, pp. : 191-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature

By  

Oncology Research and Treatment, Vol. 34, Iss. 10, 2011-09 ,pp. : 538-542

Karger

Access to resources Recommend Favorite

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

By Muszbek Noemi   Shah Sonalee   Carroll Stuart   McDonald Heather   Dale Peter   Maroun Jean   Knox Jennifer  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3559-3569

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1591-1602

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade

By  

HEPATOLOGY, Vol. 62, Iss. 6, 2015-12 ,pp. : 1791-1803

John Wiley & Sons Inc

Access to resources Recommend Favorite